Is Alexis converting to big Pharma?

Quote






Right now their sales approach is to sell off the desks, chairs, and anything else that isn't bolted down to recoup the loss of moving to New Haven in the first place.
 






The leadership learned everything they know from Big Pharma, CEO, CCO are primary care failures who struck it lucky with Baxalta. Stock is a disaster, pulled earnings around July 4th, that behavior got the old CEO and CFO fired. Anyone with any savvy is gone (Max) analysts pricing at $130 HOLD at $120 that would be a dream. No becoming, has become... if you have talent go to any of the transformative companies in Cambridge, if your in the field look and quick. MOaB is no longer a big deal, but gene therapy is... good luck.
 
























anonymous said:
Most rare disease companies these days are taking on the “big Pharma” approach to sales. Do you see that happening here?
Click to expand...
rare disease makes no difference, big or small, pharma is pharma, KPIs, reach and frequency and heaven forbid you get stuck with sampling, that's the only benefit of specialty, no samples and less traffic but still big pharma, it's all the same, only mgt makes it different in what they require, hospital makes a difference if you have multiple call points but still pharma in the end and nothing is secure anymore and the small companies will layoff entire field forces just like the big ones, knowing the VP and CEO makes no difference, they all answer to the board!!! any if it's owned by a venture capitalist RUN!!!
 






Top Bottom
Back
Quote